<>
Intensive, long-term blood pressure-lowering treatment reduces the risk of recurrent stroke by 38% in survivors of spontaneous intracerebral hemorrhage, according to a major meta-analysis published in The Lancet Neurology. Researchers analyzing individual-level data from four randomized controlled trials involving 2,944 adults found that aggressive management lowers cardiovascular events without increasing serious adverse events, challenging traditional clinical guidelines for secondary stroke prevention.
Clinical Trial Findings and Risk Reduction
During a follow-up period of up to six years, a recurrent stroke of any type occurred in 6.5% of patients assigned to intensive blood pressure-lowering regimens, compared with 10.4% of those receiving standard care or less intensive treatment, according to data published in The Lancet Neurology. Professor Craig Anderson, senior author and Senior Professorial Fellow at The George Institute for Global Health, stated that the findings provide compelling evidence for stricter blood pressure targets after an intracerebral hemorrhage (ICH).
“Our analysis shows that intensive blood pressure treatment can prevent 16 recurrent strokes for every 1,000 patients treated within the first year alone,” Professor Anderson said, as reported by News-Medical. Throughout the follow-up period, the average systolic blood pressure reached 127 mm Hg in the intensive treatment group, compared with 138 mm Hg in the control arm.
Safety Profiles and Cardiovascular Outcomes
The meta-analysis evaluated multiple clinical endpoints, noting an adjusted hazard ratio of 0.62 for the first recurrent stroke of any type, according to data covered by Healio. Researchers also observed an adjusted hazard ratio of 0.67 for major adverse cardiovascular events and 0.39 for recurrent intracerebral hemorrhage events specifically. The data showed no statistically significant differences in rates of ischemic stroke, cardiovascular death, nonvascular death, or all-cause mortality.
Serious adverse events occurred in 28.9% of patients in the intensive group, compared with 33% of patients in the standard care group. According to the study authors, this absence of an excess in serious complications demonstrates that aggressive blood pressure reduction can be implemented safely within structured clinical care pathways.
Implications for Global Guidelines and Patient Care
More than three million people experience an intracerebral hemorrhage each year, leaving an estimated 17 million survivors worldwide who face a high risk of cardiovascular death or recurrence. Subgroup analyses demonstrated that the benefits of intensive blood pressure lowering remained consistent across different baseline blood pressure levels, patient ages, sexes, and clinical severities.
Patients whose baseline systolic blood pressure was already at or below conventional targets—such as 130 mm Hg or lower—still experienced substantial risk reduction from intensive intervention. Professor Anderson noted that these findings challenge existing medical assumptions. While conventional guidelines typically recommend treatment to a target below 130/80 mm Hg, the study indicates that patients at or below this threshold remain at risk and can benefit from further reduction through fixed-dose combination therapies and structured treatment titration protocols.
>